Elizabeth Trehu is Chief Medical Officer at Jounce Therapeutics, Inc. (JNCE). They have made 10 open-market trades across 1 company since 2018, most recently 2023-01-10.
CIK 0001693456
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| JNCE | 108,543 | $204K |
Shares reported on the most recent Form 4, priced at the 2023-01-11 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| JNCE | SELL | 2023-01-09 | 2023-01-11 | $1.11 | $10K | -4.0% | -11.2% | +49.6% |
| JNCE | SELL | 2022-01-07 | 2022-01-11 | $6.88 | $58K | -2.4% | +21.2% | +0.0% |
| JNCE | SELL | 2021-03-29 | 2021-03-31 | $10.09 | $136K | -10.4% | -8.6% | -36.2% |
| JNCE | SELL | 2021-01-20 | 2021-01-22 | $12.01 | $78K | +0.2% | -12.2% | -28.4% |
| JNCE | SELL | 2021-01-07 | 2021-01-11 | $6.89 | $36K | +74.8% | +72.1% | +27.2% |
| JNCE | SELL | 2020-08-14 | 2020-08-18 | $4.71 | $10K | +4.0% | +100.2% | +55.5% |
| JNCE | SELL | 2020-01-07 | 2020-01-10 | $7.78 | $20K | -12.1% | -20.7% | -36.1% |
| JNCE | SELL | 2019-08-14 | 2019-08-16 | $3.99 | $9K | -9.4% | -14.6% | +30.5% |
| JNCE | SELL | 2018-03-08 | 2018-03-12 | $25.06 | $228K | -9.2% | -24.7% | -73.1% |
| JNCE | SELL | 2018-03-05 | 2018-03-07 | $21.39 | $165K | +21.5% | -17.2% | -65.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.